Advertisement

Headache

  • Dmitri Souza
  • Irena Kiliptch
  • Alex Feoktistov
Chapter

Abstract

Headache is one of the most common pain disorders, and the most common cause of absenteeism from school and from work. Chronic headaches affect around 15% of the general population, causing various levels of disability, family, and social dysfunction. It is associated with high socioeconomic impact. A multidisciplinary approach based on a close collaboration between neurologists and interventional pain physicians is critical to optimize outcome in patients with refractory headaches.

Keywords

Headache Migraine Tension headache Cluster headache Headache classification 

References

  1. 1.
    Friedman AP. The headache in history, literature, and legend. Bull N Y Acad Med. 1972;48(4):661–81.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Guerrero-Peral AL, de Frutos Gonzalez V, Pedraza-Hueso MI. Galeata: chronic migraine independently considered in a medieval headache classification. J Headache Pain. 2014;15:16.CrossRefGoogle Scholar
  3. 3.
    Green D. New cure for headache found in old Greek manuscript. N Y State J Med. 1974;74(9):1671–5.PubMedGoogle Scholar
  4. 4.
    Huppert D, Brandt T. Descriptions of vestibular migraine and Meniere’s disease in Greek and Chinese antiquity. Cephalalgia. 2017;37(4):385–90.CrossRefGoogle Scholar
  5. 5.
    Magiorkinis E, Diamantis A, Mitsikostas DD, Androutsos G. Headaches in antiquity and during the early scientific era. J Neurol. 2009;256(8):1215–20.CrossRefGoogle Scholar
  6. 6.
    Rose FC. The history of migraine from Mesopotamian to Medieval times. Cephalalgia. 1995;15(Suppl 15):1–3.PubMedGoogle Scholar
  7. 7.
    Rosner F. Neurology in the Bible and Talmud. Isr J Med Sci. 1975;11(4):385–97.PubMedGoogle Scholar
  8. 8.
    Albers L, von Kries R, Heinen F, Straube A. Headache in school children: is the prevalence increasing? Curr Pain Headache Rep. 2015;19(3):4.CrossRefGoogle Scholar
  9. 9.
    Burch RC, Loder S, Loder E, Smitherman TA. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache. 2015;55(1):21–34.CrossRefGoogle Scholar
  10. 10.
    Smitherman TA, Burch R, Sheikh H, Loder E. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. Headache. 2013;53(3):427–36.CrossRefGoogle Scholar
  11. 11.
    Steiner TJ, Birbeck GL, Jensen R, Katsarava Z, Martelletti P, Stovner LJ. The Global Campaign, World Health Organization and Lifting The Burden: collaboration in action. J Headache Pain. 2011;12(3):273–4.CrossRefGoogle Scholar
  12. 12.
    Ferrante T, Manzoni GC, Russo M, Camarda C, Taga A, Veronesi L, et al. Prevalence of tension-type headache in adult general population: the PACE study and review of the literature. Neurol Sci. 2013;34(Suppl 1):S137–8.CrossRefGoogle Scholar
  13. 13.
    Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight project. J Headache Pain. 2010;11(4):289–99.CrossRefGoogle Scholar
  14. 14.
    Olesen J. International Classification of Headache Disorders, Second Edition (ICHD-2): current status and future revisions. Cephalalgia. 2006;26(12):1409–10.CrossRefGoogle Scholar
  15. 15.
    Olesen J. ICHD-3 beta is published. Use it immediately. Cephalalgia. 2013;33(9):627–8.CrossRefGoogle Scholar
  16. 16.
    Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.Google Scholar
  17. 17.
    Loder S, Sheikh HU, Loder E. The prevalence, burden, and treatment of severe, frequent, and migraine headaches in US minority populations: statistics from National Survey studies. Headache. 2015;55(2):214–28.CrossRefGoogle Scholar
  18. 18.
    Snoer A, Lund N, Beske R, Jensen R, Barloese M. Pre-attack signs and symptoms in cluster headache: characteristics and time profile. Cephalalgia. 2018;38(6):1128–37.CrossRefGoogle Scholar
  19. 19.
    Fischera M, Marziniak M, Gralow I, Evers S. The incidence and prevalence of cluster headache: a meta-analysis of population-based studies. Cephalalgia. 2008;28(6):614–8.CrossRefGoogle Scholar
  20. 20.
    Alstadhaug KB, Ofte HK. Cluster headache. Tidsskr Nor Laegeforen. 2015;135(15):1361–4.CrossRefGoogle Scholar
  21. 21.
    May A. Diagnosis and clinical features of trigemino-autonomic headaches. Headache. 2013;53(9):1470–8.CrossRefGoogle Scholar
  22. 22.
    Bussone G. Strictly unilateral headaches: considerations of a clinician. Neurol Sci. 2014;35(Suppl 1):71–5.CrossRefGoogle Scholar
  23. 23.
    Robbins L. Refractory headache definition. Headache. 2011;51(2):310–1.CrossRefGoogle Scholar
  24. 24.
    Schulman EA, Lake AE 3rd, Goadsby PJ, Peterlin BL, Siegel SE, Markley HG, et al. Defining refractory migraine and refractory chronic migraine: proposed criteria from the Refractory Headache Special Interest Section of the American Headache Society. Headache. 2008;48(6):778–82.CrossRefGoogle Scholar
  25. 25.
    Levin M. Refractory headache: classification and nomenclature. Headache. 2008;48(6):783–90.CrossRefGoogle Scholar
  26. 26.
    Silberstein SD, Dodick DW, Pearlman S. Defining the pharmacologically intractable headache for clinical trials and clinical practice. Headache. 2010;50(9):1499–506.CrossRefGoogle Scholar
  27. 27.
    Schwedt TJ, Silberstein SD. 14th International Headache Congress: clinical highlights. Headache. 2010;50(3):509–19.CrossRefGoogle Scholar
  28. 28.
    Nizard J, Raoul S, Nguyen JP, Lefaucheur JP. Invasive stimulation therapies for the treatment of refractory pain. Discov Med. 2012;14(77):237–46.PubMedGoogle Scholar
  29. 29.
    Welch KM, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache. 2001;41(7):629–37.CrossRefGoogle Scholar
  30. 30.
    Maizels M, Aurora S, Heinricher M. Beyond neurovascular: migraine as a dysfunctional neurolimbic pain network. Headache. 2012;52(10):1553–65.CrossRefGoogle Scholar
  31. 31.
    Dichgans M, Freilinger T, Eckstein G, Babini E, Lorenz-Depiereux B, Biskup S, et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet. 2005;366(9483):371–7.CrossRefGoogle Scholar
  32. 32.
    Westergaard ML, Hansen EH, Glumer C, Olesen J, Jensen RH. Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. Cephalalgia. 2014;34(6):409–25.CrossRefGoogle Scholar
  33. 33.
    Rossi P, Faroni JV, Tassorelli C, Nappi G. Advice alone versus structured detoxification programmes for complicated medication overuse headache (MOH): a prospective, randomized, open-label trial. J Headache Pain. 2013;14:10.CrossRefGoogle Scholar
  34. 34.
    Chiang CC, Schwedt TJ, Wang SJ, Dodick DW. Treatment of medication-overuse headache: a systematic review. Cephalalgia. 2016;36(4):371–86.CrossRefGoogle Scholar
  35. 35.
    Limmroth V, Biondi D, Pfeil J, Schwalen S. Topiramate in patients with episodic migraine: reducing the risk for chronic forms of headache. Headache. 2007;47(1):13–21.CrossRefGoogle Scholar
  36. 36.
    Zanchin G. Chapter 25: headache: an historical outline. Handb Clin Neurol. 2010;95:375–86.CrossRefGoogle Scholar
  37. 37.
    Rapoport AM. The therapeutic future in headache. Neurol Sci. 2012;33(Suppl 1):S119–25.CrossRefGoogle Scholar
  38. 38.
    Wrobel Goldberg S, Silberstein SD. Targeting CGRP: a new era for migraine treatment. CNS Drugs. 2015;29(6):443–52.CrossRefGoogle Scholar
  39. 39.
    Edvinsson L. The CGRP pathway in migraine as a viable target for therapies. Headache. 2018;58 Suppl 1:33–47.CrossRefGoogle Scholar
  40. 40.
    Hoffmann J, Charles A. Glutamate and its receptors as therapeutic targets for migraine. Neurotherapeutics. 2018;15(2):361–70.CrossRefGoogle Scholar
  41. 41.
    Nattagh-Eshtivani E, Sani MA, Dahri M, Ghalichi F, Ghavami A, Arjang P, et al. The role of nutrients in the pathogenesis and treatment of migraine headaches: review. Biomed Pharmacother. 2018;102:317–25.CrossRefGoogle Scholar
  42. 42.
    Mojica J, Mo B, Ng A. Sphenopalatine ganglion block in the management of chronic headaches. Curr Pain Headache Rep. 2017;21(6):27.CrossRefGoogle Scholar
  43. 43.
    Castien RF, van der Wouden JC, De Hertogh W. Pressure pain thresholds over the cranio-cervical region in headache: a systematic review and meta-analysis. J Headache Pain. 2018;19(1):9.CrossRefGoogle Scholar
  44. 44.
    Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(19):1818–26.CrossRefGoogle Scholar
  45. 45.
    Cadalso RT Jr, Daugherty J, Holmes C, Ram S, Enciso R. Efficacy of electrical stimulation of the occipital nerve in intractable primary headache disorders: a systematic review with meta-analyses. J Oral Facial Pain Headache. 2018;32(1):40–52.CrossRefGoogle Scholar
  46. 46.
    Starling A. Noninvasive neuromodulation in migraine and cluster headache. Curr Opin Neurol. 2018;31(3):268–73.PubMedGoogle Scholar
  47. 47.
    Hedborg K, Muhr C. The influence of multimodal behavioral treatment on the consumption of acute migraine drugs: a randomized, controlled study. Cephalalgia. 2012;32(4):297–307.CrossRefGoogle Scholar
  48. 48.
    Foroughipour M, Golchian AR, Kalhor M, Akhlaghi S, Farzadfard MT, Azizi H. A sham-controlled trial of acupuncture as an adjunct in migraine prophylaxis. Acupunct Med. 2014;32(1):12–6.CrossRefGoogle Scholar
  49. 49.
    Ernst MM, O’Brien HL, Powers SW. Cognitive-behavioral therapy: how medical providers can increase patient and family openness and access to evidence-based multimodal therapy for pediatric migraine. Headache. 2015;55(10):1382–96.CrossRefGoogle Scholar
  50. 50.
    Seng EK, Holroyd KA. Behavioral migraine management modifies behavioral and cognitive coping in people with migraine. Headache. 2014;54(9):1470–83.CrossRefGoogle Scholar
  51. 51.
    Ashkenazi A, Blumenfeld A, Napchan U, Narouze S, Grosberg B, Nett R, et al. Peripheral nerve blocks and trigger point injections in headache management – a systematic review and suggestions for future research. Headache. 2010;50(6):943–52.CrossRefGoogle Scholar
  52. 52.
    Palamar D, Uluduz D, Saip S, Erden G, Unalan H, Akarirmak U. Ultrasound-guided greater occipital nerve block: an efficient technique in chronic refractory migraine without aura? Pain Physician. 2015;18(2):153–62.PubMedGoogle Scholar
  53. 53.
    Tang Y, Kang J, Zhang Y, Zhang X. Influence of greater occipital nerve block on pain severity in migraine patients: a systematic review and meta-analysis. Am J Emerg Med. 2017;35(11):1750–4.CrossRefGoogle Scholar
  54. 54.
    Zhang H, Yang X, Lin Y, Chen L, Ye H. The efficacy of greater occipital nerve block for the treatment of migraine: a systematic review and meta-analysis. Clin Neurol Neurosurg. 2018;165:129–33.CrossRefGoogle Scholar
  55. 55.
    Abd-Elsayed A, Kreuger L, Wheeler S, Robillard J, Seeger S, Dulli D. Radiofrequency ablation of pericranial nerves for treating headache conditions: a promising option for patients. Ochsner J. 2018;18(1):59–62.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Dmitri Souza
    • 1
  • Irena Kiliptch
    • 2
  • Alex Feoktistov
    • 3
  1. 1.Western Reserve Hospital, Heritage College of Osteopathic Medicine, Ohio UniversityCuyahoga FallsUSA
  2. 2.Avalon University School of MedicineTorontoCanada
  3. 3.Clinical ResearchDiamond Health ClinicGlenviewUSA

Personalised recommendations